| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FSH |
| Uniprot No | P23945 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-366AA |
| 氨基酸序列 | CHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRVIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLPNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKNGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLENLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQEVDYMTQARGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIMGYNILR |
| 预测分子量 | 44.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组FSH蛋白的参考文献及摘要概括：
1. **文献名称**：*"Recombinant human follicle-stimulating hormone (r-hFSH) improves spermatogenesis in men with congenital hypogonadotropic hypogonadism"*
**作者**：Pitteloud N 等
**摘要**：研究证明重组FSH联合hCG治疗可显著促进先天性低促性腺激素性性腺功能减退症患者的精子生成，为男性不育治疗提供依据。
2. **文献名称**：*"Comparison of recombinant human FSH and urinary FSH in polycystic ovary syndrome patients undergoing IVF"*
**作者**：Bayar U 等
**摘要**：对比研究显示，重组FSH在PCOS患者的IVF周期中与尿源性FSH疗效相当，但卵巢过度刺激综合征(OHSS)发生率更低，安全性更优。
3. **文献名称**：*"Expression and purification of biologically active recombinant human FSH in Chinese hamster ovary cells"*
**作者**：Olijve W 等
**摘要**：报道了利用CHO细胞表达系统高效生产具有生物活性的重组FSH，并优化纯化工艺，为工业化生产奠定技术基础。
(注：以上文献为示例，实际引用时需核对原文准确性)
Follicle-Stimulating Hormone (FSH) is a glycoprotein hormone critical for regulating reproductive processes. In humans, it stimulates ovarian follicle growth in females and spermatogenesis in males. Traditionally, FSH for therapeutic use was purified from human or animal sources, but these methods faced challenges like limited supply, batch variability, and ethical concerns.
The advent of recombinant DNA technology in the 1980s enabled the production of recombinant FSH (rFSH). By inserting the human FSH β- and α-subunit genes into mammalian cell lines (typically Chinese Hamster Ovary cells), scientists achieved consistent, large-scale production of bioactive FSH without relying on biological donors. This innovation addressed purity and scalability issues while minimizing immunogenicity risks.
Recombinant FSH revolutionized fertility treatments, becoming a cornerstone in assisted reproductive technologies (ART) like IVF. Compared to urinary-derived FSH, it offers superior batch-to-batch consistency, higher specific activity, and reduced contamination risks. Commercially available rFSH products (e.g., follitropin alfa and beta) demonstrate improved clinical outcomes in ovarian stimulation protocols.
Beyond clinical applications, rFSH serves as a vital research tool for studying FSH receptor signaling, reproductive disorders, and developing targeted therapies. Recent advances include long-acting FSH analogs and biosimilar developments to enhance treatment convenience and accessibility. Ongoing research explores its potential in treating conditions like polycystic ovary syndrome (PCOS) and age-related fertility decline.
The development of rFSH exemplifies how biotechnology transforms endocrine therapeutics, combining molecular biology precision with clinical needs to address global reproductive health challenges.
×
